|
시장보고서
상품코드
2057557
mRNA 치료제 CDMO 시장 보고서(2035년)mRNA Therapeutics CDMO Global Market Opportunities And Strategies To 2035 |
||||||
The Business Research Company
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.
가격
※ 부가세 별도
한글목차
영문목차
세계의 mRNA 치료제 CDMO 시장은 2020년에 24억 5,880만 달러로 평가되었고, 2025년까지 연평균 복합 성장률(CAGR) 13.0% 이상으로 성장했습니다.
메신저 리보핵산(mRNA) 치료제 수탁 개발 및 제조 기관(CDMO)은 제약회사나 바이오테크놀러지 기업에 대해, mRNA 기반 의약품 개발, 스케일 업 및 상업 생산을 지원하는 전문 서비스 제공업체입니다. 이러한 조직은 mRNA 합성, 지질 나노입자(LNP) 제제, 분석 시험, 프로세스 최적화, 임상 및 상업 용도용 GMP 준거 생산이라고 하는 통합 서비스를 제공합니다. mRNA 치료제 CDMO 주요 목적은 기업이 자사내에 제조 시설을 건설할 필요없고, mRNA 기반 의약품이나 백신을 신속하고 확실하며 고품질에 생산할 수 있도록 하는 것입니다.
높은 제조 비용
높은 제조 비용은 과거 mRNA 치료제 CDMO 시장의 성장을 저해하는 요인으로 작용했습니다. mRNA 치료제를 생산하기 위해서는 고가의 원료, 첨단 바이오프로세스 장비, 엄격한 오염 관리, 고도의 기술력을 갖춘 인력이 필요합니다. 또한, 복잡한 제제 공정, 콜드체인 보관 및 엄격한 품질 테스트는 운영 비용을 더욱 증가시켰습니다. 이러한 높은 비용은 많은 생명공학 및 제약회사들에게 아웃소싱의 경제적 매력을 떨어뜨리고, 후보물질의 후기 개발 단계로의 전환을 지연시키는 요인이 되고 있습니다. 또한, CDMO 업체들도 규제에 부합하는 시설 건설과 생산능력 확대를 위해 막대한 설비투자를 해야 하는 상황입니다. 그 결과, mRNA 기반 치료제에 대한 과학적 관심이 높아지고 있음에도 불구하고, 수익성 압박과 예산 제약으로 인해 시장 확대가 억제되었습니다. 예를 들어, 미국에 본사를 둔 제약회사 머크 앤 컴퍼니(Merck &Co., Inc.)의 보고에 따르면, 불활성화 백신의 총 비용에서 재료비가 차지하는 비율은 약 23%인 반면, mRNA 백신의 경우 약 81%에 달하고, mRNA 제조의 비용 구조가 상당히 높은 비용구조를 가지고 있음을 알 수 있습니다. mRNA 백신 비용의 대부분은 일상적인 운영 재료, 특히 플라스미드 직선화, 전사 및 효소 반응 단계에 기인합니다. 이는 제조 공정 중 가장 비용이 많이 드는 공정입니다. 따라서 높은 제조비용이 mRNA 치료제 CDMO 시장의 성장을 저해하고 있었습니다.
인더스트리 4.0과 스마트 제조
mRNA 치료제 CDMO 시장에서 사업을 전개하는 주요 기업들은 효율성 향상, 오염 위험 감소, 그리고 mRNA 백신 및 유전자 치료제의 신속한 개발을 지원하기 위해 플라스미드 DNA 생산의 자동화 및 속도 향상에 주력하고 있습니다. 인더스트리 4.0과 스마트 제조는 전통적인 제조의 많은 문제를 극복하고 보다 스마트하고 효율적이며 고도로 제어된 생산 공정을 가능하게 함으로써 mRNA 치료제 CDMO의 전망을 앞당기는 데 있어 점점 더 중요해지고 있습니다. 기존의 mRNA 생산은 체외 전사, 효소 반응, 무균 처리, 지질 나노입자(LNP) 제형화, 엄격한 품질 테스트 등 복잡한 공정을 거쳐야 하며, 이 모든 과정에서 정확성, 재현성, 엄격한 규제 준수가 요구됩니다. 실시간 데이터 분석, 첨단 센서, 머신러닝, 디지털 트윈, 자동 공정 제어와 같은 인더스트리 4.0 기술을 통합하여 워크플로우 전반에 걸쳐 가시성과 제어력을 향상시키고, 변동성을 줄이며, 수율을 향상시킬 수 있습니다.
세계 mRNA 치료제 CDMO 시장은 비교적 집중되어 있으며, 주요 기업들이 시장에서 사업을 전개하고 있습니다. 2024년 기준, 시장 상위 10개 경쟁업체가 전체 시장의 36.7%를 차지했습니다.
자주 묻는 질문
목차
제1장 주요 요약
제2장 목차
제3장 표 리스트
제4장 그래프 리스트
제5장 보고서 구성
제6장 시장 특징
제7장 mRNA 치료제 CDMO 시장 : 주요 제품 및 서비스 개요
제8장 주요 시장 동향
제9장 mRNA 치료제 CDMO 시장 : 성장 분석 및 전략적 분석 프레임워크
제10장 세계의 mRNA 치료제 CDMO 시장 : 규모 및 성장 분석
제11장 세계의 mRNA 치료제 CDMO 시장 : 규모(TAM) 분석
제12장 세계의 mRNA 치료제 CDMO 시장 : 시장 세분화
제13장 mRNA 치료제 CDMO 시장 : 지역별 및 국가별 분석
제14장 아시아태평양 시장
제15장 동남아시아 시장
제16장 서유럽 시장
제17장 동유럽 시장
제18장 북미 시장
제19장 남미 시장
제20장 중동 시장
제21장 아프리카 시장
제22장 경쟁 구도 및 기업 개요
제23장 기타 주요 기업 및 혁신 기업
제24장 경쟁 벤치마킹
제25장 경쟁 대시보드
제26장 mRNA 치료제 CDMO 시장 : 기업 평가 매트릭스
제27장 mRNA 치료제 CDMO 시장 : 신규 기업
제28장 주요 인수합병(M&A)
제29장 최근 동향 : mRNA 치료제 CDMO 시장
제30장 기회와 전략
제31장 mRNA 치료제 CDMO 시장 : 결론과 제안
제32장 부록
AJYThe messenger ribonucleic acid (mRNA) therapeutics contract development and manufacturing organization (CDMO) is a specialized service provider that supports pharmaceutical and biotechnology companies in the development, scale-up, and commercial manufacturing of mRNA-based medicines. These organizations offer integrated services such as mRNA synthesis, lipid nanoparticle (LNP) formulation, analytical testing, process optimization, and GMP-compliant production for clinical and commercial use. The primary purpose of an mRNA therapeutics CDMO is to enable fast, reliable, and high-quality production of mRNA-based drugs and vaccines without requiring companies to build in-house manufacturing facilities.
The global mRNA therapeutics CDMO market was valued at $2,458.8 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 13.0%.
High Manufacturing Costs
High manufacturing costs hindered the growth of the mRNA therapeutics CDMO market in the historic period. Producing mRNA therapies requires expensive raw materials, advanced bioprocessing equipment, strict contamination controls, and highly skilled technical personnel. In addition, complex formulation processes, cold-chain storage, and rigorous quality testing further increased operational expenses. For many biotech and pharmaceutical companies, these high costs reduced the economic attractiveness of outsourcing or slowed the progression of candidates into later development stages. CDMOs also faced substantial capital investments to build compliant facilities and expand capacity. As a result, profitability pressures and budget constraints restrained market expansion despite growing scientific interest in mRNA-based therapeutics. For instance, according to the Merck & Co., Inc., a US-based pharmaceutical company, reported that material costs account for only about 23% of total expenses for inactivated vaccines, compared with roughly 81% for mRNA vaccines, highlighting the significantly higher cost structure of mRNA production. Most mRNA vaccine costs stem from daily operational materials, particularly during plasmid linearization, transcription, and enzymatic reaction stages, which are the most expensive steps in the process. Therefore, high manufacturing costs hindered the growth of the mRNA therapeutics CDMO market.
Industry 4.0 And Intelligent Manufacturing
Major companies operating in the mRNA therapeutics CDMO market are focusing on automating and accelerating plasmid DNA production to improve efficiency, reduce contamination risk, and support rapid development of mRNA vaccines and gene therapies. Industry 4.0 and intelligent manufacturing are increasingly critical to advancing the mRNA therapeutics CDMO landscape by enabling smarter, more efficient, and highly controlled production processes that overcome many historical manufacturing challenges. Traditional mRNA manufacturing involves complex steps such as in-vitro transcription, enzymatic reactions, sterile processing, lipid nanoparticle (LNP) formulation, and stringent quality testing, all of which demand precision, reproducibility, and stringent regulatory compliance. Integrating Industry 4.0 technologies-such as real-time data analytics, advanced sensors, machine learning, digital twins, and automated process control-enhances visibility and control across these workflows, reducing variability and improving yield.
The global mRNA therapeutics CDMO market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 36.7% of the total market in 2024.
mRNA Therapeutics CDMO Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global mRNA therapeutics CDMO market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for mRNA therapeutics CDMO? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mRNA therapeutics CDMO market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider mRNA therapeutics CDMO market; and compares it with other markets.
The report covers the following chapters
- Introduction And Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future technologies and developments in the market.
- Growth Analysis And Strategic Analysis- Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Regional And Country Analysis- Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by type of service, by indication, by application and by end user in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
- Regional Market Size And Growth- Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments- Information on recent developments in the market covered in the report.
- Other Major And Innovative Companies- Details on the startups, company profiles of other major and innovative companies in the market.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for mRNA Therapeutics CDMO providers in terms of product/service offerings geographic expansion, marketing strategies and target groups
- Appendix This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
- 1) By Type Of Service: Development Services; Manufacturing Services; Laboratory Services
- 2) By Indication: Infectious Diseases; Metabolic And Genetic Diseases; Cardiovascular And Cerebrovascular Diseases; Oncology; Other Indications
- 3) By Application: Viral Vaccines; Protein Replacement Therapies; Cancer Immunotherapies
- 4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic Institutions; Research Organizations
- Companies Mentioned: Lonza Group; Thermo Fisher Scientific Inc. (Patheon); Samsung Biologics Co. Ltd.; Wuxi Biologics (WuXi Vaccines); Catalent, Inc. (Catalent Biologics Inc.)
- Countries: China; Australia; India; Indonesia; Japan; South Korea; Taiwan; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
- Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time-series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; mRNA therapeutics CDMO indicators comparison.
- Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1 Executive Summary
- 1.1 Dashboard
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
- 6.1 General Market Definition
- 6.2 Summary
- 6.3 mRNA Therapeutics CDMO Market Definition And Segmentations
- 6.4 Market Segmentation By Type Of Service (Development Services, Manufacturing Services, Laboratory Services)
- 6.5 Market Segmentation By Indication (Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases, Oncology And Other Indications)
- 6.6 Market Segmentation By Application (Viral Vaccines, Protein Replacement Therapies And Cancer Immunotherapies)
- 6.7 Market Segmentation By End User (Pharmaceutical Companies, Biotechnology Companies, Academic Institutions And Research Organizations)
7 mRNA Therapeutics CDMO Market, Overview Of Key Products/Services
- 7.1 mRNA Therapeutics CDMO Market, Overview Of Key Products/Services
- 7.2 Global mRNA Therapeutics CDMO Market Attractiveness Scoring And Analysis
- 7.2.1 Overview Of Market Attractiveness Framework
- 7.2.2 Quantitative Scoring Methodology
- 7.2.3 Market Attractiveness Scoring And Interpretation
- 7.2.4 Factor-Wise Evaluation
- 7.2.5 Strategic Implications And Recommendations
8 Major Market Trends
- 8.1 Key Technologies & Future Trends
- 8.1.1 Biotechnology, Genomics And Precision Medicine
- 8.1.2 Industry 4.0 And Intelligent Manufacturing
- 8.1.3 Digitalization, Cloud, Big Data And Cybersecurity
- 8.1.4 Sustainability, Climate Tech And Circular Economy
- 8.2 Major Trends
- 8.2.1 Integrated Sequence Optimization And GMP Manufacturing Partnership Accelerates mRNA Program Development
- 8.2.2 Artificial Intelligence And Autonomous Intelligence
- 8.2.3 Advancement Of Next-Generation Lipid Nanoparticle Delivery Platforms
- 8.2.4 Strategic Platform-Manufacturing Collaboration Accelerates Scalable mRNA Development
- 8.2.5 Rapid Personalized mRNA Manufacturing Enables Breakthrough Gene-Editing Therapies
- 8.2.6 Large-Scale Manufacturing Expansion Strengthens Regional mRNA Supply And Readiness
9 mRNA Therapeutics CDMO Growth Analysis And Strategic Analysis Framework
- 9.1 Global mRNA Therapeutics CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors)
- 9.1.1 Political
- 9.1.2 Economic
- 9.1.3 Social
- 9.1.4 Technological
- 9.1.5 Environmental
- 9.1.6 Legal
- 9.2 Analysis Of End User (B2C) Market
- 9.2.1 Pharmaceutical Companies
- 9.2.2 Biotechnology Companies
- 9.2.3 Academic Institutions
- 9.2.4 Research Organizations
10 Global mRNA Therapeutics CDMO Market Size And Growth Analysis
- 10.1 Historic Market Growth, 2020 - 2025, Value ($ Million)
- 10.1.1 Market Drivers 2020 - 2025
- 10.1.2 Market Restraints 2020 - 2025
- 10.2 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
- 10.3 Forecast Growth Contributors/Factors
- 10.3.1 Quantitative Growth Contributors
- 10.3.2 Drivers
- 10.3.3 Restraints
11 Global mRNA Therapeutics CDMO Total Addressable Market (TAM) Analysis
- 11.1 Definition And Scope of Total Addressable Market (TAM)
- 11.2 Methodology And Assumptions
- 11.2.1 Total Addressable Market for the mRNA Therapeutics CDMO Market - Business to Customer (B2C)
- 11.2.2 TAM Comparison Analysis
12 Global mRNA Therapeutics CDMO Market Segmentation
- 12.1 Global mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 12.2 Global mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 12.3 Global mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 12.4 Global mRNA Therapeutics CDMO Market, Segmentation By End User, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 12.5 Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Development Services, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 12.6 Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Manufacturing Services, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 12.7 Global mRNA Therapeutics CDMO Market, Sub-Segmentation Of Laboratory Services, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
13 mRNA Therapeutics CDMO Market, Regional and Country Analysis
- 13.1 Global mRNA Therapeutics CDMO Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 13.2 Global mRNA Therapeutics CDMO Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14 Asia-Pacific Market
- 14.1 Asia-Pacific Market Summary
- 14.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 14.3 Asia Pacific mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.4 Asia Pacific mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.5 Asia Pacific mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.6 China Market
- 14.6.1 China Market Summary
- 14.6.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 14.6.3 China mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.6.4 China mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.6.5 China mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.7 India Market
- 14.7.1 India mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.7.2 India mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.7.3 India mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.8 Japan Market
- 14.8.1 Japan Market Summary
- 14.8.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 14.8.3 Japan mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.8.4 Japan mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.8.5 Japan mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.9 Australia Market
- 14.9.1 Australia mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.9.2 Australia mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.9.3 Australia mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.10 South Korea Market
- 14.11 South Korea Market Summary
- 14.11.1 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 14.11.2 South Korea mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.11.3 South Korea mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.11.4 South Korea mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.12 Taiwan Market
- 14.13 Taiwan Market Summary
- 14.13.1 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 14.13.2 Taiwan mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.13.3 Taiwan mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 14.13.4 Taiwan mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
15 South East Asia Market
- 15.1 South East Asia Market Summary
- 15.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 15.2.1 South East Asia mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 15.2.2 South East Asia mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 15.2.3 South East Asia mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 15.3 Indonesia Market
- 15.3.1 Indonesia mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 15.3.2 Indonesia mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 15.3.3 Indonesia mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
16 Western Europe Market
- 16.1 Western Europe Market Summary
- 16.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 16.3 Western Europe mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.4 Western Europe mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.5 Western Europe mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.6 UK Market
- 16.6.1 UK mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.6.2 UK mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.6.3 UK mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.7 Germany Market
- 16.7.1 Germany mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.7.2 Germany mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.7.3 Germany mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.8 France Market
- 16.8.1 France mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.8.2 France mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.8.3 France mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.9 Italy Market
- 16.9.1 Italy mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.9.2 Italy mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.9.3 Italy mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.10 Spain Market
- 16.10.1 Spain mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.10.2 Spain mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 16.10.3 Spain mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
17 Eastern Europe Market
- 17.1 Eastern Europe Market Summary
- 17.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 17.3 Eastern Europe mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.4 Eastern Europe mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.5 Eastern Europe mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.6 Russia Market
- 17.6.1 Russia mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.6.2 Russia mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 17.6.3 Russia mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
18 North America Market
- 18.1 North America Market Summary
- 18.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 18.3 North America mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.4 North America mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.5 North America mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.6 USA Market
- 18.6.1 USA Market Summary
- 18.6.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 18.6.3 USA mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.6.4 USA mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.6.5 USA mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.7 Canada Market
- 18.7.1 Canada Market Summary
- 18.7.2 Market Overview (Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 18.7.3 Canada mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.7.4 Canada mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 18.7.5 Canada mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
19 South America Market
- 19.1 South America Market Summary
- 19.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments And Major Companies)
- 19.3 South America mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.4 South America mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.5 South America mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.6 Brazil Market
- 19.6.1 Brazil mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.6.2 Brazil mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 19.6.3 Brazil mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
20 Middle East Market
- 20.1 Middle East Market Summary
- 20.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 20.3 Middle East mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 20.4 Middle East mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 20.5 Middle East mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
21 Africa Market
- 21.1 Africa Market Summary
- 21.2 Market Overview (Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure And Major Companies)
- 21.3 Africa mRNA Therapeutics CDMO Market, Segmentation By Type Of Service, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 21.4 Africa mRNA Therapeutics CDMO Market, Segmentation By Indication, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
- 21.5 Africa mRNA Therapeutics CDMO Market, Segmentation By Application, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
22 Competitive Landscape And Company Profiles
- 22.1 mRNA Therapeutics CDMO Market Competitive Landscape And & Market Share 2024
- 22.1.1 Top 10 Companies (Ranked by revenue/share)
- 22.2 Company Profiles
- 22.3 Lonza Group (Company Overview, Products and Services, Business Strategy, Financial Overview)
- 22.4 Thermo Fisher Scientific Inc. (Patheon) (Company Overview, Products and Services, Business Strategy, Financial Overview)
- 22.5 Samsung Biologics Co. Ltd (Company Overview, Products and Services, Business Strategy, Financial Overview)
- 22.6 Wuxi Biologics (WuXi Vaccines) (Company Overview, Products and Services, Business Strategy, Financial Overview)
- 22.7 Catalent, Inc. (Catalent Biologics Inc.) (Company Overview, Products and Services, Business Strategy, Financial Overview)
23 Other Major And Innovative Companies
- 23.1 Danaher Corp. (Aldevron) (Company Overview, Products and Services)
- 23.2 Merck KGaA (Merck Millipore) (Company Overview, Products and Services)
- 23.3 AGC Biologics GmbH (Company Overview, Products and Services)
- 23.4 Genscript Biotech Corp. (ProBio) (Company Overview, Products and Services)
- 23.5 FUJIFILM Holdings Corporation (Fujifilm Pharmaceuticals U.S.A., Inc) (Company Overview, Products and Services)
- 23.6 Recipharm AB (Company Overview, Products and Services)
- 23.7 Wacker Chemie AG (Company Overview, Products and Services)
- 23.8 ST Pharm (Company Overview, Products and Services)
- 23.9 Corden Pharma Corp. (Company Overview, Products and Services)
- 23.10 Rentschler Biopharma SE (Company Overview, Products and Services)
- 23.11 eTheRNA manufacturing (Company Overview, Products and Services)
- 23.12 Biomay AG (Company Overview, Products and Services)
- 23.13 TriLink BioTechnologies LLC (Company Overview, Products and Services)
- 23.14 Biocina Pty Ltd. (Company Overview, Products and Services)
- 23.15 Bio-Synthesis Inc. (Company Overview, Products and Services)
24 Competitive Benchmarking
25 Competitive Dashboard
26 mRNA Therapeutics CDMO Market - Company Scoring Matrix
- 26.1 Innovation & Brand Leaders
- 26.2 Brand-Driven Traditionalists
- 26.3 Niche or Regional Followers
- 26.4 Emerging Innovators
27 Upcoming Startups In the mRNA Therapeutics CDMO Market
28 Key Mergers And Acquisitions
- 28.1 Novo Holdings A/S Acquired Catalent Inc.
- 28.2 Agilent Technologies Acquired BIOVECTRA
29 Recent Developments In mRNA Therapeutics CDMO
- 29.1 Grant-Funded Initiative To Scale Open-Access mRNA Vaccine Inputs And Strengthen Global Health Equity
- 29.2 GMP Clearance Enables Commercial-Scale Advanced Therapy Manufacturing
30 Opportunities And Strategies
- 30.1 Global mRNA Therapeutics CDMO Market In 2030 - Countries Offering Most New Opportunities
- 30.2 Global mRNA Therapeutics CDMO Market In 2030 - Segments Offering Most New Opportunities
- 30.3 Global mRNA Therapeutics CDMO Market In 2030 - Growth Strategies
- 30.3.1 Market Trend Based Strategies
- 30.3.2 Competitor Strategies
31 mRNA Therapeutics CDMO Market, Conclusions And Recommendations
- 31.1 Conclusions
- 31.2 Recommendations
- 31.2.1 Product
- 31.2.2 Place
- 31.2.3 Price
- 31.2.4 Promotion
- 31.2.5 People
32 Appendix
- 32.1 Geographies Covered
- 32.2 Market Data Sources
- 32.3 Research Methodology
- 32.4 Currencies
- 32.5 The Business Research Company
- 32.6 Copyright and Disclaimer
